Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer

Mansoor Raza Mirza, MD
Published: Monday, Apr 02, 2018



Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

A retrospective analysis of the phase III ENGOT-OV16/NOVA trial showed that baseline body weight and platelet counts were early predictors for future adverse event-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PARP inhibitors have changed the course of disease for patients with ovarian cancer, says Mirza. Next steps include investigating mechanisms of resistance, patient selection, and combinations with antiangiogeneic drugs and immune checkpoint inhibitors.


Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

A retrospective analysis of the phase III ENGOT-OV16/NOVA trial showed that baseline body weight and platelet counts were early predictors for future adverse event-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PARP inhibitors have changed the course of disease for patients with ovarian cancer, says Mirza. Next steps include investigating mechanisms of resistance, patient selection, and combinations with antiangiogeneic drugs and immune checkpoint inhibitors.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x